Neovasc (NASDAQ:NVCN) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Neovasc (NASDAQ:NVCN – Get Rating) (TSE:NVC) in a research report report published on Tuesday. The firm issued a sell rating on the medical equipment provider’s stock.

NVCN has been the topic of several other reports. Bloom Burton lowered shares of Neovasc from a buy rating to a hold rating in a research report on Wednesday, January 18th. HC Wainwright lowered shares of Neovasc from a buy rating to a neutral rating in a research report on Wednesday, January 18th.

Neovasc Stock Performance

Shares of NVCN opened at $27.76 on Tuesday. Neovasc has a 12 month low of $4.59 and a 12 month high of $28.28. The firm has a fifty day simple moving average of $13.98 and a 200 day simple moving average of $9.34. The stock has a market capitalization of $76.15 million, a price-to-earnings ratio of -2.26 and a beta of 1.72. The company has a current ratio of 8.44, a quick ratio of 8.13 and a debt-to-equity ratio of 0.43.

Neovasc (NASDAQ:NVCN – Get Rating) (TSE:NVC) last announced its earnings results on Thursday, November 10th. The medical equipment provider reported ($3.00) EPS for the quarter, missing the consensus estimate of ($2.82) by ($0.18). Neovasc had a negative return on equity of 78.98% and a negative net margin of 1,077.37%. The business had revenue of $0.92 million for the quarter, compared to analyst estimates of $1.00 million. Research analysts forecast that Neovasc will post -11.95 EPS for the current fiscal year.

About Neovasc

(Get Rating)

Neovasc, Inc engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.